利拉鲁肽
医学
肾功能
内分泌学
泌尿科
内科学
糖尿病
2型糖尿病
作者
Felipe Tonon Firmino,Pollyana Peixoto,Thatiany Jardim Batista,Leonardo da Silva Escouto,Girlândia Alexandre Brasil,Mariana Couto,Antônio Ferreira de Melo,Nazaré Souza Bissoli
标识
DOI:10.1097/fjc.0000000000001649
摘要
Glucagon-like peptide-1 (GLP-1) receptor agonists exhibit beneficial cardiovascular effects. However, the renal effects of different doses of liraglutide in an essential hypertension model have not yet been investigated. SHR female rats were treated for 30 days, twice a day, with saline (control) or liraglutide at low (0.06 mg/kg, LL) and high (0.6 mg/kg, LH) doses. Volume intake and excretion were monitored for a period of 24h. In renal tissue, nitrite-NO2-, nitrate-NO3-, advanced protein oxidation products-AOPP, collagen deposition, creatinine (Cr), urea (U), sodium, and potassium were analyzed. liraglutide reduced body weight gain in both groups. However, in the high dose, it increased urinary volume excretion and sodium/potassium ratio. Both doses reduced the urinary U/Cr ratio and LH increased the serum U/Cr ratio. AOPP was reduced only in LL. LH augmented collagen and early markers of kidney injury (blood urea nitrogen-BUN, BUN/Cr). LH increased NO3-, reduced NO2-, and caused an aberrant increase in GFR. Both doses' effects were independent of blood pressure and glycemic control. liraglutide appears to have distinct effects on the hypertensive female kidney depending on the dose, with higher doses impairing kidney function.
科研通智能强力驱动
Strongly Powered by AbleSci AI